See more : IPD Group Limited (IPG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Radius Global Infrastructure, Inc. (RADI) Income Statement Analysis – Financial Results
- U City Public Company Limited (U.BK) Income Statement Analysis – Financial Results
- Angold Resources Ltd. (AAU.V) Income Statement Analysis – Financial Results
- Huagong Tech Company Limited (000988.SZ) Income Statement Analysis – Financial Results
- Flagship Investments Limited (FSI.AX) Income Statement Analysis – Financial Results
Compugen Ltd. (CGEN)
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.46M | 7.50M | 6.00M | 2.00M | 0.00 | 17.80M | 0.00 | 712.00K | 9.28M | 12.37M | 3.55M | 242.00K | -424.00K | 1.12M | 250.00K | 338.00K | 180.00K | 215.00K | 646.00K | 4.03M | 8.83M | 11.10M | 11.36M | 6.89M | 3.24M |
| Cost of Revenue | 2.00M | 975.00K | 680.00K | 60.00K | 989.00K | 1.03M | 1.59M | 223.00K | 1.63M | 3.34M | 2.51M | 201.00K | 424.00K | 224.00K | 0.00 | 7.00K | 0.00 | 6.00K | 148.00K | 1.10M | 2.28M | 2.82M | 3.46M | 478.00K | -769.00K |
| Gross Profit | 31.46M | 6.53M | 5.32M | 1.94M | -989.00K | 16.77M | -1.59M | 489.00K | 7.64M | 9.02M | 1.04M | 41.00K | -848.00K | 891.00K | 250.00K | 331.00K | 180.00K | 209.00K | 498.00K | 2.93M | 6.55M | 8.28M | 7.91M | 6.41M | 4.01M |
| Gross Profit Ratio | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | 200.00% | 79.91% | 100.00% | 97.93% | 100.00% | 97.21% | 77.09% | 72.68% | 74.22% | 74.60% | 69.59% | 93.06% | 123.76% |
| Research & Development | 34.47M | 30.65M | 28.69M | 22.76M | 19.82M | 30.32M | 28.58M | 24.55M | 21.25M | 15.07M | 12.28M | 9.44M | 6.78M | 5.23M | 5.05M | 8.75M | 8.39M | 9.81M | 10.47M | 12.32M | 13.31M | 14.17M | 15.98M | 12.17M | 6.68M |
| General & Administrative | 9.73M | 10.32M | 10.86M | 9.81M | 8.41M | 8.04M | 7.63M | 7.35M | 6.01M | 5.45M | 4.85M | 3.46M | 4.59M | 2.91M | 2.15M | 3.50M | 0.00 | 0.00 | 0.00 | 3.61M | 4.38M | 5.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 244.00K | 932.00K | 842.00K | 871.00K | 651.00K | 1.63M | 1.19M | 1.17M | 1.31M | 838.00K | 962.00K | 684.00K | 610.00K | 633.00K | 681.00K | 996.00K | 0.00 | 0.00 | 0.00 | 5.54M | 6.57M | 3.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.98M | 11.25M | 11.70M | 10.68M | 9.06M | 9.68M | 8.82M | 8.52M | 7.32M | 6.29M | 5.81M | 4.14M | 5.20M | 3.54M | 2.83M | 4.50M | 4.25M | 4.39M | 4.91M | 6.19M | 7.46M | 9.15M | 10.95M | 9.18M | 4.32M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -523.00K | -811.00K | -588.00K | 281.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.82M | 18.44M | 13.89M | 0.00 | 0.00 | 1.86M |
| Operating Expenses | 44.45M | 41.90M | 40.39M | 33.44M | 28.88M | 39.99M | 37.41M | 33.07M | 28.56M | 21.36M | 18.08M | 13.58M | 11.98M | 8.77M | 7.88M | 13.24M | 12.64M | 14.20M | 15.38M | 18.50M | 20.77M | 23.32M | 26.92M | 21.35M | 12.85M |
| Cost & Expenses | 46.45M | 42.87M | 41.07M | 33.50M | 28.88M | 41.03M | 37.41M | 33.30M | 30.20M | 24.70M | 20.59M | 13.78M | 11.98M | 8.99M | 7.88M | 13.25M | 12.64M | 14.21M | 15.52M | 19.60M | 23.04M | 26.14M | 30.38M | 21.83M | 12.09M |
| Interest Income | 3.24M | 1.74M | 894.00K | 1.77M | 935.00K | 643.00K | 523.00K | 728.00K | 815.00K | 346.00K | 169.00K | 301.00K | 0.00 | 0.00 | 0.00 | 502.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 31.00K | 27.00K | 25.00K | 42.00K | 32.00K | 620.00K | 508.00K | 705.00K | 755.00K | 330.00K | 141.00K | 240.00K | -306.00K | 241.00K | 65.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 476.00K | 482.00K | 461.00K | 715.00K | 989.00K | 1.39M | 1.59M | 1.48M | 1.11M | 658.00K | 370.00K | 299.00K | 179.00K | 201.00K | 264.00K | 477.00K | 633.00K | 996.00K | 2.39M | 1.76M | 2.68M | 2.90M | 4.28M | 4.99M | 1.86M |
| EBITDA | -12.52M | -35.37M | -34.61M | -31.50M | -27.04M | -21.83M | -35.46M | -31.10M | -19.81M | -12.34M | -17.04M | -13.27M | -11.81M | -7.68M | -7.37M | -12.03M | -11.83M | -13.08M | -12.49M | -13.81M | -12.20M | -12.15M | -14.74M | -9.94M | -6.99M |
| EBITDA Ratio | -37.41% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,891.51% | -767.09% | -4,566.00% | -3,835.80% | -6,578.33% | -6,095.81% | -1,967.49% | -353.89% | -138.26% | -109.45% | -126.73% | -145.13% | -215.32% |
| Operating Income | -12.99M | -35.37M | -35.07M | -31.50M | -28.88M | -23.23M | -37.41M | -32.58M | -20.92M | -12.34M | -17.04M | -13.54M | -11.98M | -7.88M | -7.63M | -12.91M | -12.46M | -13.99M | -14.88M | -15.58M | -14.22M | -15.04M | -19.02M | -16.18M | -8.85M |
| Operating Income Ratio | -38.83% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,825.24% | -706.55% | -3,051.60% | -3,820.12% | -6,922.22% | -6,508.37% | -2,303.10% | -386.81% | -161.07% | -135.57% | -167.42% | -234.74% | -273.34% |
| Total Other Income/Expenses | 3.21M | 1.74M | 871.00K | 1.80M | 820.00K | 628.00K | 339.00K | 1.10M | 1.15M | 1.76M | 3.46M | -86.00K | 0.00 | 675.00K | 3.79M | 401.00K | 1.00M | 1.94M | 900.00K | 1.86M | 2.77M | 2.84M | -348.00K | 1.30M | -18.00K |
| Income Before Tax | -9.78M | -33.64M | -34.20M | -29.70M | -28.06M | -22.60M | -37.07M | -31.49M | -19.77M | -10.73M | -13.58M | -13.63M | -12.00M | -7.44M | -3.84M | -12.51M | -11.46M | -13.88M | -14.66M | -15.14M | -13.55M | -13.40M | -19.37M | -14.87M | -8.87M |
| Income Before Tax Ratio | -29.24% | -448.48% | -570.05% | -1,484.90% | 0.00% | -126.96% | 0.00% | -4,422.19% | -213.14% | -86.80% | -382.73% | -5,631.40% | 2,831.13% | -667.62% | -1,537.20% | -3,701.48% | -6,365.56% | -6,457.67% | -2,269.35% | -375.94% | -153.57% | -120.79% | -170.48% | -215.85% | -273.90% |
| Income Tax Expense | 8.97M | 58.00K | -1.33M | -2.44M | -722.00K | -1.26M | -678.00K | 20.00K | 390.00K | 360.00K | 500.00K | -416.00K | 331.00K | -1.35M | -7.58M | -37.00K | 32.00K | -1.08M | -1.12M | -2.29M | -3.44M | -2.84M | -3.53M | -1.59M | -701.00K |
| Net Income | -18.75M | -33.69M | -32.87M | -27.26M | -27.34M | -22.60M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12.00M | -7.20M | -3.83M | -12.53M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.20M | -15.14M | -13.40M | -8.13M |
| Net Income Ratio | -56.05% | -449.25% | -547.88% | -1,363.00% | 0.00% | -126.96% | 0.00% | -4,425.00% | -217.34% | -89.71% | -396.82% | -5,631.40% | 2,831.13% | -646.01% | -1,532.40% | -3,706.21% | -6,730.00% | -6,055.81% | -2,163.78% | -340.75% | -129.64% | -109.98% | -133.31% | -194.51% | -251.13% |
| EPS | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| EPS Diluted | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| Weighted Avg Shares Out | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 47.81M | 38.87M | 35.84M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
| Weighted Avg Shares Out (Dil) | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical...
Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial...
Compugen Reports Fourth Quarter and Full Year 2023 Results
Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolio Solid balance sheet with extended cash runway expected to...
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami...
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
HOLON, Israel , Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd.
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D.
7 Speculative Stocks to Double Your Money THIS Year
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense.
Source: https://incomestatements.info
Category: Stock Reports